Podcasts about Kras

We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Jahrzehntelang galt KRAS als „undruggable“ – also als therapeutisch nicht angreifbar. Jetzt sorgen Daten einer Phase-3-Studie beim metastasierten Pankreaskarzinom weltweit für Aufsehen. In dieser Folge sprechen Tom Lüdde, Christoph Roderburg und Petra Lynen über die neue RAS-Inhibition mit Daraxonrasib: Was unterscheidet den Wirkstoff von bisherigen KRAS-Inhibitoren? Warum sind die Ergebnisse der Phase-3-Studie so außergewöhnlich? Und stehen wir tatsächlich am Beginn einer neuen Ära für Patientinnen und Patienten mit KRAS-mutiertem Pankreaskarzinom? Neben den beeindruckenden Überlebensdaten geht es auch um Nebenwirkungen, Lebensqualität, ethische Aspekte und natürlich die Frage, wann die neue Therapie in Deutschland verfügbar sein wird. Ein Gespräch über einen der spannendsten Durchbrüche der GI-Onkologie der letzten Jahre.

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Send us Fan MailS4E4 The Oncology Journal Club Podcast In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting's most talked-about studies and discuss what they could mean for clinical practice.From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

On this week's episode, Yaron Werber, Tess Cameron, SamFazeli, and Brian Skorney kick off with a look at markets, noting that while AI remains hot, biotech may be cooling amid anticipated tech IPOs. The co-hosts note that biotech saw a significant recovery over the past year driven by M&A and improving sentiment, highlighting that the XBI has remained remarkably stable. The discussion then turns to policy, where momentum to expand the COINS Act into biotech raises concerns. The group highlights the need to distinguish between manufacturing supply chains, where national security risks are real, and innovation ecosystems, where restricting capital flows could slow drug development and shift advantage outside of the US. Recapping the highlights from ASCO 2026, Akeso/Summit's ivonescimab showed meaningful survival benefits, while Revolution Medicines' KRAS program in pancreatic cancer stood out as a breakthrough, receiving a standing ovation at the conference. In breast cancer, the focus was centered on emerging CDK4 selective inhibitors from Pfizer and others. Grail's multi-cancer early detection readout was also discussed, along with in vivo CAR-T data from Kelonia that showed strong early responses but raised durability questions. *This episode aired on June 5, 2026.

BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health in Tallahassee, Florida. Pancreatic ductal adenocarcinoma is among the deadliest forms of cancer, due in large part to the high frequency of KRAS mutations that drive tumor growth and resistance to treatment. Although targeted therapies have recently been developed for specific KRAS mutations, many patients continue to have limited treatment options, highlighting the need for broader strategies capable of targeting multiple KRAS-driven cancers. In this study, researchers investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors (PCAIs), which were originally designed to disrupt abnormal KRAS signaling. Using pancreatic cancer cell lines carrying KRAS mutations, the team explored how these compounds affect cancer cell survival, migration, invasion, and the molecular pathways that regulate tumor growth. Full press release - https://www.oncotarget.com/news/pr/experimental-compounds-trigger-cancer-cell-death-in-kras-driven-pancreatic-cancer/ DOI - https://doi.org/10.18632/oncotarget.28879 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Olur öyle. İnsanız. Boş bulunuruz. Münasebetsiz, ucunun nereye gideceğini o an hesap edemediğimiz bir patavatsızlık, bir hata yapabiliriz. Sonra pişman olur, özür diler ve bağışlanma dileriz.

2026 年 5 月底，一项名为 RESolute 302 的三期临床试验结果登上了 ASCO 压轴场。10 多年来，胰腺癌的中位总生存期，都卡在 6 个月出头，而一款叫做 Daraxonrasib 的新药，把这个数字拉到了 13.2 个月——死亡风险下降了 60%。为什么这件事如此震撼？因为它攻克的靶点叫做 KRAS——一个 1982 年就已被发现、与三成人类癌症相关、在胰腺癌中突变率接近 95%，却被整个科学界宣判了近 40 年"不可成药"的基因。这期节目里，我们聊了聊 RAS 蛋白到底是什么，它为什么那么难成药；第一代 KRAS 药物是为什么对胰腺癌几乎无效；以及 Daraxonrasib 是怎样突破“不可成药”的极限的。时间轴[00:13] Daraxonrasib 将胰腺癌的中位生存期延长了一倍[02:30] RAS 靶点：癌症研究的珠穆朗玛峰[03:59] RAS 基...去小宇宙查看完整单集简介在小宇宙查看该单集文稿

Slováci v Austrálii: Ekonóm Martin Berka - pôsobil na univerzitách v Kanade a Novom Zélande; v súčasnosti pôsobí na Obchodnej fakulte Griffithskej univerzity v austrálskom Brisbane, kde aj žije; Hudobné momentky: Štefan Krasňanský už viac ako dvadsať rokov vyváža slovenskú hudbu do Veľkej Británie; 19. septembra 2026 organizuje v Londýne už rekordný, pätnásty koncert skupiny IMT Smile;

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

En este tercer RECAP de la Reunión Anual de la Sociedad Americana de Oncología Clínica, el Dr. Fabián Martínez conversa con el Dr. Salvador Víctor, oncólogo médico titular de la clínica de tumores urológicos del Hospital General de México y médico adscrito al Instituto Nacional de Perinatología. La sesión inicia con el abordaje del cáncer de próstata metastásico sensible a la castración a través del estudio TALAPRO-3, el cual propone la adición de un inhibidor de PARP (talazoparib) al esquema de enzalutamida y terapia de deprivación androgénica (TDA) en pacientes con alteraciones en genes de reparación de la recombinación homóloga (como ATM o CHEK2). Asimismo, en el escenario de la enfermedad localizada de alto riesgo, se evalúan los resultados del estudio PROTEUS. En este punto, se cuestiona el posicionamiento de la neoadyuvancia sistémica con apalutamida más TDA frente a la TDA aislada, considerando que el estándar actual no contempla el tratamiento neoadyuvante y que no existió una comparación directa con la radioterapia definitiva.Posteriormente, la conversación se extiende hacia el ensayo EMERALD-3 en hepatocarcinoma irresecable. Se analiza el rendimiento de combinar inmunoterapia (esquema STRIDE) y lenvatinib con quimioembolización transarterial (TACE) frente a la TACE sola. En el área de tejidos blandos, se evalúa el diseño metodológico del estudio fase III SARC-041 en liposarcoma desdiferenciado; los expertos debaten las implicaciones éticas y prácticas de emplear un brazo de control con placebo frente a abemaciclib, a pesar del impacto significativo que demostró este fármaco en la supervivencia libre de progresión. Finalmente, se revisa el estudio fase IIb TRITON en cáncer de pulmón de células no pequeñas avanzado sin alteraciones conductoras clásicas, evaluando cómo la intensificación del tratamiento con doble inmunoterapia y quimioterapia podría revertir la resistencia intrínseca en poblaciones con co-mutaciones en KRAS, STK11 y KEAP1, caracterizadas por un pronóstico adverso.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Harald Müller-Huesmann spricht mit Claas Wesseler über die wichtigsten Neuigkeiten zum Lungenkarzinom. Im Fokus stehen Langzeitüberleben unter zielgerichteten Therapien, neue molekulare Behandlungsansätze und die Frage, wie ctDNA die Thoraxonkologie künftig verändern könnte.

At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field's approach to the cancer. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Revolution's daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury's radar at this year's American Society of Clinical Oncology meeting.BioCentury's analysts also discuss a push by China hawks in Congress to get the Trump administration to invoke national security powers to narrow Chinese life sciences companies' access to U.S. markets, technology and capital; an initiative by Rep. Jake Auchincloss (D-Mass.) that seeks to modernize how clinical trials are conducted in the U.S.; and a BioCentury analysis on new antibody-drug conjugate linker techniques. This episode of the BioCentury podcast is brought to you by Jeito Capital.View full story: https://www.biocentury.com/article/659581 #Biopharma #ASCO2026 #PancreaticCancer #ClinicalTrials #ADCInnovation00:01 - Sponsor Message: Jeito Capital02:26 - ASCO Preview14:24 - U.S. China Policy22:48 - Modernizing U.S. trials27:17 - Optimizing ADC LinkersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ajax kende tegen FC Groningen een onverwachte opleving en plaatste zich daarmee voor de finale van de play-offs. Het duel in het Kras Stadion deed soms even terugdenken aan de tijden in De Meer. En Oscar Garcia deed nogal wat uitspraken waarin de realiteitszin totaal leek te ontbreken. Genoeg te bespreken dus. Lekker luisteren, gewoon doen!Volg ons ook op Instagram en TikTok!Maak jouw opstelling in de Ajax Life-app.Krijg 20% korting bij House of Marley met code ajaxlife20

Aleksander - Aleks Rebula se je v iskanju službe pred 11 leti s Krasa z nekdanjo partnerko in sinom preselil v Melbourne. Tam je ostal in se predkratkim na Filipinih poročil s sedanjo ženo. Izhaja iz družinske tradicije zborovskega petja, zato je filipinski zbor Caceres Chorale nagovoril, da se je naučil in zapel tri slovenske pesmi: Pri farni cerkvici, Čej so tiste stezice in Dajte mi zlatih strun. Presenečenje je uspelo. Programer v pogovoru razlaga tudi, zakaj je tako “zagrizen” promotor slovenske kulture, zakaj obžaluje, da je zapustil Kras - in zakaj vseeno ostaja v Avstraliji. Slovence v Melbournu poziva, naj mu predlagajo dobro pekarno, saj najbolj pogreša naš slovenski kruh. Poznate kakšnega sogovornika ali sogovornico za oddajo Globalna vas? Pišite na ursula.zaletelj@rtvslo.si. POSNETKI ZBORA Caceres Chorale: https://www.youtube.com/watch?v=2SCnPfHxdZg https://www.youtube.com/watch?v=DyU0I6sX_BE&t=314s 

Dnešným hosťom relácie Zo zákulisia politiky bol bratislavský primátor Matúš Vallo, s ktorým sme hovorili priamo v električkovom depe Krasňany v hlavnom meste. Témou nebola však len dopravná infraštruktúra, ale aj zveľaďovanie verejného priestoru či bezpečnosť v Bratislave. Rozprávali sme sa aj o parkovacej politike či kritizovam cyklopruhu na Vajanského nábreží.Ľutuje niečo Matúš Vallo ohľadom bratislavských cyklotrás? Aké úpravy čakajú Zochovu ulicu? Ako chce riešiť bezpečnosť v Starom meste? Čo ako primátor robiť nechce? Verí si v blížiacich sa voľbách? Toto všetko a ešte viac sa dozvieš v rozhovore.

This episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.  While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.  Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development. The conversation also highlights Anocca's first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.  This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.  Episode Timestamps  00:00 – Introduction to TCR-T and solid tumor challenges  00:48 – Meet Reagan Jarvis and Anocca  02:05 – From New Zealand to Sweden: founder journey  03:08 – Frustration that sparked the platform  04:33 – Why CAR-T struggles in solid tumors  07:24 – The advantage of vertical integration in biotech  09:23 – First non-viral clinical trial challenges  10:56 – Umbrella trials in pancreatic cancer (KRAS focus)  14:13 – Biomarkers and building a target library  17:08 – Software, data, and machine learning in TCR discovery  18:08 – Regulatory pathways for individualized therapies  19:19 – Commercial landscape and target bottlenecks  22:29 – Expanding beyond oncology and partnerships  23:51 – Building a biotech company in Sweden  27:12 – Misconceptions about T-cell biology  30:04 – Milestones and 5-year vision  32:32 – Advice for scientific founders  34:17 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Reagan Jarvis;  LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/  Website: https://www.anocca.com/     Follow IDEA Pharma  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Speljuntan lyfter på locket och känner doften av nyhetsveckan. Tre generaler smakar på Nintendos nostalgiska rävpepp, Sonys fylleköp av Bungie och tindrande AI-ögon som ställs i kontrast till Xbox något mer återhållsamma hållning. Innan lunchrasten är slut får vi höra om hur Antons andliga resa i keramikens tecken går i kras i spelet Kiln. Elisabeth däremot berättar om hur hon gått igenom musikvärldens b-sidor och fått styra lite tafatt ungdomshångel i coming of age-spelet Mixtape. Du som stöttar oss på Speljuntan.se kan denna vecka känna lukten av medeltid i ett prat om en parfym få såg komma. Spel som nämns i avsnittet: Star Fox, Mario, Super Smash Bros., Orbitals Marathon, Destiny, Concord, Arc Raiders, Kiln, Psychonauts, Brütal Legend, Mixtape, Fahrenheit, The Artful Escape Tidskoder: (01:01) Personliga frågan (05:30) Spelnyheter (38:32) Reklam (39:24) Spelintryck

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, Michael J. Pishvaian, MD, PhD, sat down to discuss the evolving role of biomarker-directed strategies in gastrointestinal (GI) oncology, as well as the importance of early comprehensive testing to identify molecular drivers and resistance mechanisms when approaching frontline treatment selection and sequencing. Pishvaian serves as director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the National Capital Region.Pishvaian began the discussion by highlighting the shift from a disease-site-specific approach to a molecularly defined paradigm, noting that microsatellite instability–high status and NTRK fusions now dictate therapy regardless of tumor origin. He reviewed the transformational data from the phase 3 HERIZON-GE-01 trial (NCT04276493), positing that zanidatamab (Ziihera) could become the new standard of care for HER2-positive upper GI cancers due to unprecedented survival outcomes. He also emphasized the emergence of Claudin 18.2-directed therapies, noting that data from the phase 2 ILUSTRO study (NCT03505320) demonstrates remarkable progression-free survival when adding zolbetuximab (Vyloy) to mFOLFOX6 and nivolumab (Opdivo) for high-expressing subgroups.The conversation then shifted to colorectal cancer, where Dr. Pishvaian detailed how data from the phase 3 BREAKWATER trial (NCT03845036) has "locked in" a paradigm requiring frontline testing for BRAF V600E mutations to guide the use of encorafenib (Braftovi) plus cetuximab (Erbitux). He also discussed the "care revolution" in KRAS inhibition, spotlighting the significant survival benefits seen with daraxonrasib in pancreatic cancer and the potential for novel allele-specific inhibitors to combat disease resistance.Finally, Pishvaian addressed the practicalities of implementation, noting that testing rates in the community remain low. He advocated for prioritizing testing, including liquid biopsies and ctDNA, at the time of initial diagnosis to ensure no patient is left behind.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions. Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors. Key topics covered in this episode: The significance of NGS testing and PD-L1 scores in treatment decisions The role of chemotherapy in high PD-L1 patients Insights on dual checkpoint inhibitors based on recent clinical trials The latest options for KRAS G12C mutations and C-MET overexpression Practical considerations for managing treatment-related side effects Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology. Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care! #MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess. Guests: Deborah Doroshow, MD, PhD Associate Professor of Medicine, Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai David S. Hong, MD Douglas E. Johnson Endowed Professor Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program] Division of Cancer Medicine Clinical Medical Director, Clinical and Translational Research Center The University of Texas MD Anderson Cancer Center Jonathan Riess, MD Associate Professor of Medicine, UC Davis Comprehensive Cancer Center Director of Thoracic Oncology, University of California, Davis

In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall survival (OS) compared with investigator's choice of chemotherapy, with survival benefits extending to those with different RAS mutations and RAS wild-type disease.Simeone spoke about the significance of these results in the context of the pancreatic cancer field, breaking down how daraxonrasib's mechanism of action as a pan-RAS inhibitor may open a “new fronter” beyond standard-of-care chemotherapy and platinum-based regimens. She also touched upon the prominent toxicities that have emerged with daraxonrasib, including rashes, while emphasizing the balancing of risk and benefit as part of further optimizing RAS therapeutics.The discussion also highlighted strategies for expanding genetic testing for patients with pancreatic cancer, as Simeone described the importance of receiving second opinions at comprehensive cancer centers where multidisciplinary teams can guide patients towards personalized treatment plans. She also mentioned how initiatives such as the Pancreatic Cancer Early Detection (PRECEDE) Consortium represent viable opportunities for continuing to elevate the quality of care for patients.“This has been a Holy Grail type of thing, where people have been wanting to target KRAS but it's been a challenge. This has been a breakthrough,” Simeone said regarding the results seen with daraxonrasib. “While the effect is dramatic in patients with metastatic cancer—and unfortunately that's still half of patients who walk in the door with pancreatic cancer—applying this therapy to stage I cancer could be even more profound and drive cures. Investment in early detection, partnered with these advances in therapeutics, is where we will see the most significant progress in increasing survival rates.”Simeone is the director of the Moores Cancer Center at University of California San Diego Health.ReferenceDaraxonrasib demonstrates unprecedented overall survival benefit in pivotal phase 3 RASolute 302 clinical trial in patients with metastatic pancreatic cancer. News release. Revolution Medicines. April 13, 2026. Accessed April 29, 2026. https://tinyurl.com/44t5vh5d

In this podcast, experts E. Gabriela Chiorean, MD; Tanios S. Bekaii-Saab, MD; Mitesh Borad, MD; and Christopher Lieu, MD, discuss the evolving role of KRAS-targeted therapies in pancreatic cancer, including underlying biology, emerging clinical data, and real-world challenges in treatment selection and trial access.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into an array of dynamic changes and strategic maneuvers within the industry, showcasing how these transformations are shaping the future of healthcare and patient treatment. Starting with regulatory innovation, the FDA's new initiative to facilitate real-time review of clinical trial data is a potential game-changer for drug development timelines. With AstraZeneca and Amgen participating in this pilot program, the industry anticipates a more efficient approval process that addresses issues during trials rather than post-completion. This could significantly reduce the time it takes for patients to access cutting-edge therapies, marking a pivotal shift towards more agile regulatory frameworks. Such initiatives reflect a broader move towards streamlining drug approvals without sacrificing safety and efficacy. Turning to strategic investments, AstraZeneca's renewed commitment to a £300 million investment in the UK, following earlier disputes over drug pricing, signals confidence in resolving these issues favorably. This decision underscores AstraZeneca's dedication to fostering innovation within the UK's life sciences sector. Similarly, Teva Pharmaceuticals' $700 million acquisition of Emalex Biosciences positions it to introduce a new therapy for Tourette syndrome, highlighting efforts to address conditions with limited treatment options. In oncology, GSK is aligning its strategy with industry trends by focusing on cancer therapies. Despite withdrawing from a partnership with Mersana Therapeutics and pausing its mRNA bird flu shot program, GSK aims to channel resources into more promising ventures. This reflects a broader industry focus on oncology due to its high unmet needs and market potential, which companies are eager to capitalize on through innovative treatments. Additionally, Kite Pharma is preparing for potential approval of its next-generation CAR-T therapy for multiple myeloma, representing ongoing progress in personalized medicine approaches aimed at complex diseases like cancer. Furthermore, Pfizer's Elrexfio has shown promising results in multiple myeloma trials, potentially expanding treatment options and reinforcing Pfizer's oncology market position. The competitive dynamics in Alzheimer's treatments are also noteworthy as Biogen and Eli Lilly vie for market share with Leqembi and Kisunla, respectively. This competition highlights complexities in chronic disease management where dosing differences may influence patient decisions. The biotech sector remains robust in fundraising activities despite challenges. Noteworthy is Vivacta's $50 million Series A round and Coultreon's $125 million fundraising effort, indicating strong investor confidence in biotech innovations. These financial injections are vital for advancing ambitious projects that promise transformative impacts on patient care. Strategic acquisitions continue to shape the industry landscape. Chiesi Group's $1.9 billion acquisition of KalVista Pharmaceuticals exemplifies this trend, focusing on expanding rare disease offerings—a niche market with significant unmet needs but fewer competitors. Meanwhile, AbbVie's acquisition option for Kestrel Therapeutics underscores its strategic expansion into targeted cancer therapies, particularly through Kestrel's promising oral pan-KRAS inhibitor. In regulatory scrutiny news, AstraZeneca's camizestrant faces intense evaluation ahead of advisory committee meetings. Such scrutiny ensures that only effective treatments reach the market while emphasizing the rigorous standards required during drug development processes. Lastly, technological integration within pharmaceutical operations is becoming increasingly crucial as companies leverage AI to enhance R&D efficiency and accelerate value crSupport the show

In this in-depth episode of the Project Purple Podcast, CEO & Founder Dino Verrelli welcomes Dr. Despina Siolas, a physician-scientist at Cornell University whose work spans both the clinic and the research lab. With an M.D. from Stony Brook School of Medicine, a Ph.D. in genetics from Cold Spring Harbor Laboratory, and medical oncology training at NYU, Dr. Siolas brings a unique perspective to the fight against pancreatic cancer. Dr. Siolas shares her personal journey into medicine, inspired by her mother's colon cancer diagnosis when she was just 16, and explains how her dual role as a clinician and researcher allows her to translate what she sees in the clinic directly into groundbreaking studies. She dives into the challenges and intricacies of studying KRAS mutations, found in 93% of pancreatic tumors, and how new insights and emerging therapies are finally offering hope for patients. Listeners will hear about the importance of genetic testing, the collaboration of diverse teams in her lab, and the role of patient advocacy in shaping research priorities. Dr. Siolas also discusses her experience as a woman in a traditionally male-dominated field, the necessity of systemic change in research, and how Project Purple's Recovery Grant helped her continue critical work after unexpected funding challenges. Whether you're a patient, caregiver, advocate, or science enthusiast, this episode provides a powerful look at the intersection of patient care, genetic research, and innovative treatments, highlighting how progress in the lab can directly impact lives in the clinic. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community. Read our press release to learn more about how Project Purple's Pancreatic Cancer Research Recovery Grant is helping Dr. Siolas sustain her important work: https://www.projectpurple.org/project-purple-awards-weill-cornell-medicine-375k-to-advance-pancreatic-cancer-research/ You can follow Dr. Siolas for updates on LinkedIn: https://www.linkedin.com/in/despina-siolas-md-phd-7249a982

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explored: • The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings. • The importance of germline testing and next-generation sequencing (NGS) in guiding treatment decisions. • The role of neoadjuvant and adjuvant therapies, including FOLFIRINOX and Gemcitabine-based regimens. • Strategies for managing borderline resectable disease and the significance of multidisciplinary care. • The critical aspect of supportive care, including the use of pancreatic enzyme replacement therapy. • Insights into treatment options for metastatic disease, including FOLFIRINOX, NALIRIFOX, and Gemcitabine-Nab-paclitaxel. • The emerging landscape of targeted therapies for KRAS mutations and the potential of pan-RAS inhibitors. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving treatment algorithms for pancreatic cancer. Don't forget to like, subscribe, and hit the notification bell for more discussions on cancer treatment and care! #PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

UPDATED WITH CORRECT AUDIOWhile Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mutations in colorectal cancer were historically prognostic; this has now shifted with targeted therapies available for both. In the context of metastatic colorectal cancer, BRAF mutations account for up to 10% of cases and are associated with significantly poorer overall survival compared with wild-type (WT) counterparts. The median overall survival in many cases of metastatic disease was under 15 months. Five years ago, there were no options, but now we see a growing list of potential therapeutic choices. Trials discussed today include BREAKWATER and CODEBREAK 300.Studies discussed in this episode:BREAKWATERCodebreak 300For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

New USF football coach Brian Hartline joins T-Kras from Ferg's on Rays Opening Day.

Rays TV analyst Brian Anderson joins T-Kras live from Ferg's to preview Rays Opening Day.

Hillsborough County Commissioner Ken Hagan joined T-Kras on the day the Rays are re-opening Tropicana Field.

As the Rays re-open Tropicana Field, Rays CEO of Athletics Rob Higgins joined T-Kras live from Ferg's.

Former Rays outfielder and World Series star Brett Phillips joins T-Kras LIVE from Ferg's to celebrate the re-opening of Tropicana Field.

Former major leaguer Orestes Destrade joins T-Kras and Ronnie Lane live from Ferg's to celebrate the Rays opening Tropicana Field.

Nordiskt samarbete och nya checklistor ska ge nog patienter till fas 3-studier av målsökande läkemedel mot särskilda gener vid bukspottkörtelcancer. Lyssna på alla avsnitt i Sveriges Radios app. Bukspottkörtelcancer, pankreascancer, hör till diagnoserna med sämst prognos. Många får diffusa symtom och när sjukdomen upptäcks har den ofta hunnit sprida sig med metastaser. I Sverige insjuknar omkring 1 600 personer per år. Bara runt 400 kan opereras, och endast omkring 100 lever mer än fem år. För att vända utvecklingen riktas nu ovanligt intensiv forskning mot tumörens biologi och mot nya behandlingar.Ett viktigt spår är målsökande läkemedel mot mutationer i en särskild gen, KRAS, som finns hos en stor andel av patienterna. Flera stora fas 3-studier pågår internationellt, ofta i kombination med cytostatika. Samtidigt har svenska patienter länge haft svårt att komma med i prövningarna, bland annat på grund av få patienter och krävande samordning.Nu byggs nya processer med checklistor, mallar och nordiskt samarbete för att få ihop tillräckligt många deltagare. Konsekvensen kan bli att alla som får diagnosen får sin tumör sekvenserad för att identifiera KRAS-variant och snabbare kunna matchas till rätt studie. Forskare varnar ändå för att resistens kan utvecklas. Parallellt nämns andra vägar, som cancervaccin baserade på mRNA.Reporter: Annika Östmanannika.ostman@sr.seProducent: Lars Broströmlars.brostrom@sr.se

In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in advanced non–small cell lung cancer (NSCLC).

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, IllinoisLink to full program:https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

De drömde om ett kollektivt paradis 15 år senare möts medlemmarna i rättssalen. Som fiender. Lyssna på alla avsnitt i Sveriges Radios app. Programmet är en repris och publicerades för första gången 2020.En dag syns banderoller med protestbudskap på det stora gula huset.Den här historien om när en dröm krockar in i en hård verklighet. Och om hur det är att vara ideologisk i bostadskarriärens Stockholm.Det ekologiska kollektivhuset Gebers ligger bland ekarna nere vid en strand i södra Stockholm. På landet fast i stan. Det grundades i mitten av 90-talet, av en grupp miljöengagerade unga som ville ha ett gemensamt boende.I den här dokumentären får du möta kollektivisterna, och följa med till det som kunde ha blivit ett paradis.Dokumentären är gjord 2020.Reporter: Rasmus MalmProducent: Ylva LindgrenSlutmix: Nima Shams

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this vault episode from the Transformative Leadership Summit, host Jethro Jones interviews Will Parker, a high school principal from northeastern Oklahoma, about implementing KRAs (Key Responsibility Areas) in schools. Will shares how he adapted Dave Ramsey's organizational management concept to create clarity and accountability for all staff members—from secretaries and counselors to administrators. The conversation explores how defining specific responsibility areas upfront prevents confusion, enables cross-training, improves hiring processes, and creates a supportive environment where everyone understands their role. Will emphasizes that KRAs are living documents revisited annually, helping schools manage organizational structure effectively, especially during transitions like budget cuts or staff changes.

In this episode Dr's J and Santhosh once again perform everybody's favorite segment journal club, this time with an emphasis on pancreatic stories. Along the way they cover medical etymology of the pancreas, the microbiome, changing cancer sensitivity with fecal transplants, giving a poop for science, lizard spit cancer scans, gila monsters and ozempic, PAC-MANN cancer detection, KRAS the undruggable gene, new targets for metastatic cells and more! So sit back and relax as we devour studies about the pancreas!Further Readinghttps://www.sjhc.london.on.ca/news-and-media/news/world-first-clinical-trial-will-study-specialized-poop-pills-to-improvehttps://www.popsci.com/science/gila-monster-spit-tumor/https://pubmed.ncbi.nlm.nih.gov/39937880/Support Us spiritually, emotionally or financially here! or on ACAST+travelmedicinepodcast.comBlueSky/Mastodon/X/Instagram: @doctorjcomedy @toshyfroTikotok: DrjtoksmedicineGmail: travelmedicinepodcast@gmail.comSpotify: https://open.spotify.com/show/28uQe3cYGrTLhP6X0zyEhTPatreon: https://www.patreon.com/travelmedicinepodcast Hosted on Acast. See acast.com/privacy for more information.